NCT05183698

Brief Summary

Evaluation and characterization of autofluorescence signals of tissue in and around wounds as identified by MolecuLight fluorescence image.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2022

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 7, 2021

Completed
1 month until next milestone

Study Start

First participant enrolled

January 10, 2022

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 11, 2022

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 10, 2022

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 10, 2022

Completed
Last Updated

January 11, 2022

Status Verified

January 1, 2022

Enrollment Period

4 months

First QC Date

December 7, 2021

Last Update Submit

January 4, 2022

Conditions

WoundWound of Skin

Outcome Measures

Primary Outcomes (1)

  • Spectra of autofluorescent signatures of tissue in and around the wounds

    Spectral characterization (i.e. emission curve including intensity) of the autofluorescence signal from wound tissue and surrounding tissue will be catalogued from all 50 study participants.

    2 months

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with chronic and/or acute wound

You may qualify if:

  • Patients presenting with acute or chronic wounds
  • years or older
  • Willing to consent

You may not qualify if:

  • Treatment with an investigational drug within 1 month of enrolment
  • Any contra-indication to regular wound care
  • Inability or unwillingness to consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Wounds and Injuries

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 7, 2021

First Posted

January 11, 2022

Study Start

January 10, 2022

Primary Completion

May 10, 2022

Study Completion

December 10, 2022

Last Updated

January 11, 2022

Record last verified: 2022-01